SCHEMBL727

SCHEMBL727

CCCc1cc(C(=O)O)n(C)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.51
KDM4E B2RXH2 2/20 0.50
GRN P28799 2/20 0.50
SORT1 Q99523 2/20 0.50
GAA P10253 1/20 0.43
GFER P55789 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
MAPK1 P28482 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
SMYD3 Q9H7B4 1/20 0.40
NAMPT P43490 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
NR1H4 Q96RI1 1/20 0.38
JAK1 P23458 1/20 0.38
HCAR2 Q8TDS4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2934234 0.90 KDM4E (0.47) POLBKDM4EGRNSORT1GAA
SCHEMBL8055438 0.88 POLB (0.42) POLBKDM4EGRNSORT1GAA
SCHEMBL17288712 0.88 KDM4E (0.46) POLBKDM4EGRNSORT1CA12
SCHEMBL20503261 0.87 KDM4E (0.45) POLBKDM4EGRNSORT1HCAR2
SCHEMBL13995818 0.86 POLB (0.51) POLBKDM4EGRNSORT1GAA
SCHEMBL343503 0.85 GRN (0.53) POLBKDM4EGRNSORT1CA12
SCHEMBL3055278 0.84 POLB (0.50) POLBKDM4EGRNSORT1GAA
SCHEMBL13485372 0.84 POLB (0.50) POLBKDM4EGAAGFERMAPK1
Hydrochloric Acid SCHEMBL6378087 0.84 GRN (0.51) POLBKDM4EGRNSORT1CA12
SCHEMBL8508457 0.83 GRN (0.55) POLBKDM4EGRNSORT1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115536587-B Method for preparing sildenafil intermediate by micro-channel nitration 衡阳小桔制药有限公司 2025-03-04 CN claimed
CN-115536587-A Method for preparing sildenafil intermediate by micro-channel nitration 衡阳小桔制药有限公司 2022-12-30 CN claimed
EP-3099689-B1 PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2022-01-26 EP claimed
CN-109721538-A A kind of novel synthesis of 1- methyl -3- propylpyrazol -5- carboxylic acid 孙双 2019-05-07 CN claimed
US-10017511-B2 Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2018-07-10 US claimed
US-20170066771-A1 Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-03-09 US claimed
EP-3099689-A1 PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF Council of Scientific and Industrial Research (IN) 2016-12-07 EP claimed
CN-105622512-A Nitration synthesis process applicable to industrial sildenafil midbody JINLIN MEDICAL COLLEGE 2016-06-01 CN claimed
WO-2015114647-A1 PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-08-06 WO claimed
US-6960661-B2 [7-(3-chloro-4-methoxybenzlamino)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-ylmethoxy]acetic acid, synthesis thereof and intermediates used therein MERCK PATENT GMBH (DE) 2005-11-01 US claimed
US-20040053945-A1 Process for the preparation of a pyrazolo[4,3-d]pyrimidine derivative MERCK PATENT GMBH (DE) 2004-03-18 US claimed
EP-1358189-A1 PROCESS FOR THE PREPARATION OF A PYRAZOLO 4,3-D]PYRIMIDINE DERIVATIVE MERCK PATENT GmbH (DE) 2003-11-05 EP claimed
WO-2002059126-A1 PROCESS FOR THE PREPARATION OF A PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVE MERCK PATENT GMBH (DE) 2002-08-01 WO claimed
WO-2025049827-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING PYRAZOLE DERIVATIVES OSMO LABS, PBC (US) 2025-03-06 WO disclosed
CN-115536587-B Method for preparing sildenafil intermediate by micro-channel nitration 衡阳小桔制药有限公司 2025-03-04 CN disclosed
CN-115536587-B Method for preparing sildenafil intermediate by micro-channel nitration 衡阳小桔制药有限公司 2025-03-04 CN disclosed
EP-0526004-A1 Pyrazolopyrimidinone antianginal agents Pfizer Limited (GB) 1993-02-03 EP disclosed
CN-1068329-A Pyrazolopyrimidinoneantianginal antianginal agents PFIZER (US) 1993-01-27 CN disclosed
EP-0463756-A1 Pyrazolopyrimidinone antianginal agents Pfizer Limited (GB) 1992-01-02 EP disclosed
CN-1057464-A Pyrazolopyrimidinoneantianginal antianginal agents PFIZER (US) 1992-01-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10017511-B2 Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof PDE5A, PDE3A, PDE3B POLB 2408/4885KDM4E 170/4885GRN 4204/4885
US-20170066771-A1 Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof PDE5A, PDE3A, PDE3B POLB 2408/4885KDM4E 170/4885GRN 4204/4885
US-20040053945-A1 Process for the preparation of a pyrazolo[4,3-d]pyrimidine derivative HPD, DDC, KMO POLB 607/4885KDM4E 591/4885GRN 3179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.